FIG 3.

Molecular characteristics of the molecular high-grade (MHG) group. (A) Mutation frequencies for 400 Randomized Evaluation of Molecular-Guided Therapy for Diffuse Large B-Cell Lymphoma With Bortezomib (REMoDL-B) patients in MHG, germinal center B-cell-like (GCB), unclassified (UNC), and activated B-cell-like (ABC) subgroups for the 70-gene panel (statistical significance of differences at P < .05 [single asterisks]) and P < .01 [double asterisks] by Fisher’s exact test). Known (double asterisks) and predicted (single asterisks) aberrant somatic hypermutation (SHM) target genes from Schmitz et al.⁶ (B) Heat map of gene expression signatures (bottom) and associated mutations (top; limited to genes with mutation frequency > 5% in at least one group and significantly different [P < .05] between any two groups of MHG, GCB, and ABC). The heat map shows the mean gene expression level (red = high to blue = low) over genes in the chosen signature cluster representative and is augmented in 70 patients with Burkitt lymphoma (BL) for comparison of gene expression patterns. The left-side bar chart (top) recapitulates the incidence of the corresponding mutations and their distribution among subgroups. Fb, fibroblast; NA, not applicable; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cell; NK, natural killer cell.